Biologic & Biosimilar RA Drugs Global Market Report 2025

Description

Biologics and biosimilars belong to a drug category derived from living organisms such as cells, microorganisms, and other living entities. Biosimilars are specifically designed to closely resemble an already approved biological drug. These medications are primarily used to treat rheumatoid arthritis (RA), a chronic inflammatory disorder.

The primary origins of RA drugs derived from biologics and biosimilars include microbial sources, involving bacteria, yeast, and fungi, along with mammalian and other sources. These medications are utilized to address a spectrum of diseases including oncology, immunological, cardiovascular, and hematological disorders. They are manufactured both through outsourced and in-house methods and are made available to patients through prescription and over-the-counter (OTC) channels, including hospital pharmacies, retail outlets, and online pharmacies.

The biologic & biosimilar RA drugs market research report is one of a series of new reports from The Business Research Company that provides biologic & biosimilar RA drugs market statistics, including biologic & biosimilar RA drugs industry global market size, regional shares, competitors with biologic & biosimilar RA drugs market share, detailed biologic & biosimilar RA drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the biologic & biosimilar RA drugs industry. This biologic & biosimilar RA drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologic & biosimilar ra drugs market size has grown strongly in recent years. It will grow from $13.99 billion in 2024 to $14.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies.

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $19.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare.

The growing older population and the rising incidence of rheumatoid arthritis are propelling the biologics and biosimilar RA drugs market. The older population consists of individuals aged 60 years and above, and rheumatoid arthritis is an autoimmune condition where the immune system mistakenly attacks healthy cells, primarily affecting the joints. This disease is more prevalent in older adults, as aging weakens the immune system. Biologics and biosimilar RA drugs are particularly effective in treating rheumatoid arthritis compared to conventional medications. For example, the World Health Organization (WHO), a specialized health agency of the United Nations based in Switzerland, reported that in 2020, there were approximately 1 billion people aged 60 and over globally, with projections estimating this number will rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, anticipates that the number of adults with arthritis in the USA will increase to 78.4 million by 2040, with 34.6 million experiencing activity limitations due to arthritis. Thus, the combination of a growing geriatric population and increasing cases of rheumatoid arthritis is driving the biologics and biosimilars RA drugs market forward.

Anticipated growth in healthcare spending is poised to drive the expansion of the biologic and biosimilar RA drug market. Healthcare spending encompasses the total financial outlay by individuals, governments, and organizations on medical goods and services, encompassing expenses related to health condition prevention, treatment, and management. Biologic and biosimilar RA drugs play a pivotal role in optimizing the management of rheumatoid arthritis by providing specialized and often costly treatments in a cost-effective manner. For instance, projections by the Canada-based Institute for Health Information (CIHI) indicate that total health spending in Canada is expected to reach $344 billion in 2023, amounting to $8,740 per Canadian. This represents a 2.8% growth in 2023, following a 1.5% increase in 2022. The escalating healthcare spending landscape is a key driver for the biologic and biosimilar RA drug market.

A prominent trend contributing to popularity is the introduction of new innovations in the biologic and biosimilar RA drugs market. Major industry players are concentrating on the development of biosimilar treatments, exemplified by advancements such as Dual Concentration Biosimilar Options, offering cost-effective alternatives. Noteworthy is the collaboration between Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company. In July 2023, they launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. HADLIMA, available in both high and low concentrations, aims to improve accessibility and affordability for patients with autoimmune diseases. Priced at an 85% discount to Humira, HADLIMA includes an autoinjector endorsed by the Arthritis Foundation and a patient support program called 'HADLIMA For You,' providing educational resources and co-pay support. Indicated for various conditions including rheumatoid arthritis and Crohn's disease, HADLIMA, with its dual concentration options, ensures seamless continuity of care for patients.

Leading companies in the biologic and biosimilar RA drugs market are securing approvals for groundbreaking biologics, including injectable medications, to enhance their offerings for the treatment of polymyalgia rheumatica. Injectable medications, typically administered in liquid form using a needle and syringe, are gaining prominence in expanding treatment options. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare and pharmaceutical company, obtained FDA approval for Kevzara (sarilumab) to address polymyalgia rheumatica (PMR) in adults with an inadequate response to corticosteroids or those unable to tolerate corticosteroid taper. The approval stems from positive outcomes in the SAPHYR Phase 3 trial, where Kevzara demonstrated a significant 28% sustained remission rate compared to the placebo's 10% at 52 weeks. Originally approved for rheumatoid arthritis, Kevzara stands out as the first and only biologic treatment for PMR, providing relief from its debilitating symptoms.

In November 2022, Biocon, an India-based biopharmaceutical company, completed the acquisition of Viatris' global biosimilars business for $3 billion. This acquisition serves to bring patients, consumers, and payors closer to Biocon Biologics, offering direct commercial capabilities and supporting infrastructure across various emerging and advanced markets. Viatris, a US-based pharmaceutical company, specializes in manufacturing biosimilars for treating rheumatoid arthritis and other diseases. The acquisition positions Biocon Biologics to strengthen its presence and expand its reach in the biosimilars business, further solidifying its standing in the competitive landscape.

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biologic & biosimilar ra drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologic & Biosimilar RA Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologic & biosimilar ra drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologic & biosimilar ra drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologic & biosimilar ra drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Source: Microbial; Mammalian; Other Sources
2) By Disease: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Other Diseases
3) By Manufacturing: Outsourced; In-House
4) By Mode Of Purchase: Prescription Drugs; Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources; Fungal Sources; Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources; Insect-Based Sources; Synthetic Biology Approaches
Companies Mentioned: Samsung BioLogics Co. Ltd.; Amgen Inc.; Novo Nordisk A/S; AbbVie Inc.; Johnson & Johnson Services Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23204

1. Executive Summary

2. Biologic & Biosimilar RA Drugs Market Characteristics

3. Biologic & Biosimilar RA Drugs Market Trends And Strategies

4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biologic & Biosimilar RA Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Biologic & Biosimilar RA Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biologic & Biosimilar RA Drugs Market Growth Rate Analysis
5.4. Global Biologic & Biosimilar RA Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biologic & Biosimilar RA Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biologic & Biosimilar RA Drugs Total Addressable Market (TAM)

6. Biologic & Biosimilar RA Drugs Market Segmentation

6.1. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Microbial
Mammalian
Other Sources
6.2. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Other Diseases
6.3. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Outsourced
In-House
6.4. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prescription Drugs
Over-The-Counter (OTC) Drugs
6.5. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Microbial, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bacterial Sources
Fungal Sources
Yeast Sources
6.7. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Mammalian, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chinese Hamster Ovary (CHO) Cells
Human Embryonic Kidney (HEK) Cells
Other Mammalian Cell Lines
6.8. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Other Sources, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plant-Based Sources
Insect-Based Sources
Synthetic Biology Approaches

7. Biologic & Biosimilar RA Drugs Market Regional And Country Analysis

7.1. Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biologic & Biosimilar RA Drugs Market

8.1. Asia-Pacific Biologic & Biosimilar RA Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biologic & Biosimilar RA Drugs Market

9.1. China Biologic & Biosimilar RA Drugs Market Overview
9.2. China Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biologic & Biosimilar RA Drugs Market

10.1. India Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biologic & Biosimilar RA Drugs Market

11.1. Japan Biologic & Biosimilar RA Drugs Market Overview
11.2. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biologic & Biosimilar RA Drugs Market

12.1. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biologic & Biosimilar RA Drugs Market

13.1. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biologic & Biosimilar RA Drugs Market

14.1. South Korea Biologic & Biosimilar RA Drugs Market Overview
14.2. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biologic & Biosimilar RA Drugs Market

15.1. Western Europe Biologic & Biosimilar RA Drugs Market Overview
15.2. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biologic & Biosimilar RA Drugs Market

16.1. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biologic & Biosimilar RA Drugs Market

17.1. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biologic & Biosimilar RA Drugs Market

18.1. France Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biologic & Biosimilar RA Drugs Market

19.1. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biologic & Biosimilar RA Drugs Market

20.1. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biologic & Biosimilar RA Drugs Market

21.1. Eastern Europe Biologic & Biosimilar RA Drugs Market Overview
21.2. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biologic & Biosimilar RA Drugs Market

22.1. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biologic & Biosimilar RA Drugs Market

23.1. North America Biologic & Biosimilar RA Drugs Market Overview
23.2. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biologic & Biosimilar RA Drugs Market

24.1. USA Biologic & Biosimilar RA Drugs Market Overview
24.2. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biologic & Biosimilar RA Drugs Market

25.1. Canada Biologic & Biosimilar RA Drugs Market Overview
25.2. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biologic & Biosimilar RA Drugs Market

26.1. South America Biologic & Biosimilar RA Drugs Market Overview
26.2. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biologic & Biosimilar RA Drugs Market

27.1. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biologic & Biosimilar RA Drugs Market

28.1. Middle East Biologic & Biosimilar RA Drugs Market Overview
28.2. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biologic & Biosimilar RA Drugs Market

29.1. Africa Biologic & Biosimilar RA Drugs Market Overview
29.2. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biologic & Biosimilar RA Drugs Market Competitive Landscape And Company Profiles

30.1. Biologic & Biosimilar RA Drugs Market Competitive Landscape
30.2. Biologic & Biosimilar RA Drugs Market Company Profiles
- 30.2.1. Samsung BioLogics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Biologic & Biosimilar RA Drugs Market Other Major And Innovative Companies

31.1. Pfizer Inc.
31.2. Merck & Co. Inc.
31.3. Eli Lilly and Company
31.4. Novartis AG
31.5. Bayer AG
31.6. F. Hoffmann-La Roche Ltd.
31.7. AstraZeneca PLC
31.8. Teva Pharmaceutical Industries Ltd.
31.9. Fresenius Se & Co. KGaA
31.10. Stada Arzneimittel AG
31.11. Boehringer Ingelheim Pharmaceuticals Inc.
31.12. Gedeon Richter Plc.
31.13. La Roche Ltd.
31.14. Regeneron Pharmaceuticals Inc.
31.15. Bristol-Myers Squibb Company

32. Global Biologic & Biosimilar RA Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biologic & Biosimilar RA Drugs Market

34. Recent Developments In The Biologic & Biosimilar RA Drugs Market

35. Biologic & Biosimilar RA Drugs Market High Potential Countries, Segments and Strategies

35.1 Biologic & Biosimilar RA Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Biologic & Biosimilar RA Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Biologic & Biosimilar RA Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer